Use of Decision Support Tools to Empower Pregnant Women: Systematic Review

Ngo, Elin; Truong, Maria Bich-Thuy; Nordeng, Hedvig

doi:10.2196/19436

Cited by 22 publications

(17 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier studies have shown that the majority of the pregnant population owns a smartphone and over 50% use apps related to pregnancy [ 36 ]. Studies that have investigated the use of health-related apps have shown that the apps could improve the knowledge levels of pregnant women and the apps were perceived as tools during pregnancy [ 7 , 24 ]. Except for user satisfaction, our results were not consistent with those from previous studies.…”

Section: Discussionmentioning

confidence: 99%

“…Our review from 2020, consistent with previous studies [ 48 ], demonstrated that decision support tools could potentially provide benefit to pregnant women. However, the tools were mainly useful when relevant information was assembled into one digital tool and when the woman could share her recordings with her health care provider [ 7 ]. Based on the results of this study, future research should focus on how to design trials to determine the effect of digital tools on the pregnancy outcomes that are most important to pregnant patients.…”

Section: Discussionmentioning

confidence: 99%

“…However, available studies have shown that apps could have a positive impact on the knowledge level of pregnant women, when integrated as part of patient care. Pregnant women also seemed to appreciate and were satisfied with digital tools [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

“…A prior study showed that integrating apps into professional clinical services could potentially improve the effectiveness of health care [ 26 ]. Our previous review concluded that the innovative use of eHealth initiatives and digitalization could potentially empower pregnant patients and improve maternal care [ 7 ]. However, at the same time, a more scientific approach is needed for testing and evaluating these apps and other digital tools.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Impact of a Mobile Application for Tracking Nausea and Vomiting During Pregnancy (NVP) on NVP Symptoms, Quality of Life, and Decisional Conflict Regarding NVP Treatments: MinSafeStart Randomized Controlled Trial

Ngo¹,

Truong²,

Nordeng³

et al. 2022

JMIR Mhealth Uhealth

Self Cite

View full text Add to dashboard Cite

Background Pregnant women are active users of mobile apps for health purposes. These apps may improve self-management of health-related conditions. Up to 70% of pregnant women experience nausea and vomiting (NVP). Even mild NVP can significantly reduce quality of life (QoL), and it can become an economic burden for both the woman and society. NVP often occurs before the first maternal care visit; therefore, apps can potentially play an important role in empowering pregnant women to recognize, manage, and seek appropriate treatment for NVP, when required. Objective This study investigated whether the MinSafeStart (MSS) mobile app could impact NVP-related symptoms, QoL, and decisional conflict regarding NVP treatment. Methods This randomized controlled trial enrolled 268 pregnant women with NVP in Norway from 2019 to 2020. The intervention group had access to the MSS app, which could be used to track NVP symptoms and access tailored advice. NVP severity was rated with the Pregnancy Unique Quantification of Emesis (PUQE) score. The control group followed standard maternal care. We collected data on maternal baseline characteristics, NVP severity, QoL, and decisional conflict using 2 sets of online questionnaires. One set of questionnaires was completed at enrollment, and the other was completed after 2 weeks. We performed linear regression analyses to explore whether the use of the MSS app was associated with NVP severity, QoL, or decisional conflict. Results Among the 268 women enrolled in the study, 192 (86.5%) completed the baseline questionnaires and were randomized to either the intervention (n=89) or control group (n=103). In the intervention group, 88 women downloaded the app, and 468 logs were recorded. In both groups, women were enrolled at a median of 8 gestational weeks. At baseline, the average PUQE scores were 4.9 and 4.7; the average QoL scores were 146 and 149; and the average DCS scores were 40 and 43 in the intervention and control groups, respectively. The app had no impact on NVP severity (aβ 0.6, 95% Cl −0.1 to 1.2), QoL (aβ −5.3, 95% Cl −12.5 to 1.9), or decisional conflict regarding NVP treatment (aβ −1.1, 95% Cl −6.2 to 4.2), compared with standard care. Conclusions Tracking NVP symptoms with the MSS app was not associated with improvements in NVP symptoms, QoL, or decisional conflict after 2 weeks, compared with standard care. Future studies should include a process evaluation to improve our understanding of how pregnant women use the app and how to optimize its utility within maternity care. Specifically, studies should focus on how digital tools might facilitate counseling and communication between pregnant women and health care providers regarding NVP management during pregnancy. Trial Registration ClinicalTrails.gov (NCT04719286): https://www.clinicaltrials.gov/ct2/show/NCT04719286

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of a Mobile Application for Tracking Nausea and Vomiting During Pregnancy (NVP) on NVP Symptoms, Quality of Life, and Decisional Conflict Regarding NVP Treatments: MinSafeStart Randomized Controlled Trial

Ngo¹,

Truong²,

Nordeng³

et al. 2022

JMIR Mhealth Uhealth

Self Cite

View full text Add to dashboard Cite

show abstract

“…Medication reviews provided by pharmacists have showed increased knowledge and compliance, and a more positive attitude toward medication use [18]. Earlier studies have demonstrated that pharmaceutical care improves health outcomes, con dence in decision-making, knowledge, and communication and is cost-effective as well [19,20]. We have previously found that a pharmacist intervention for pregnant women in the rst trimester was feasible and highly appreciated by the women themselves [21,22].…”

Section: Introductionmentioning

confidence: 99%

Impact of a primary care pharmacist intervention on pregnant women`s medication use: The SafeStart intervention study linked to a national prescription database

Ngo

Truong

Nordeng

2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background Prior studies show that pharmacists’ consultations are highly appreciated by pregnant women and feasible in community pharmacies. However, it is unknown whether such counselling has an impact on medication use during pregnancy. Aim This study aimed to assess whether a pharmacist consultation in early pregnancy was associated with pregnant woman’s utilization of medications with focus on antiemetic medications. Methods The SafeStart study recruited Norwegian, pregnant women in the first trimester between February 2018 and February 2019. Women in the intervention group received a pharmacist consultation in a community pharmacy or by phone. An online follow-up questionnaire was completed 13 weeks after enrollment. Data from the SafeStart study was linked to the Norwegian Prescription Database. Logistic regression was used to assess the association between the pharmacists’ intervention and medication use in second trimester. Results The study included 103 women in the intervention group and 126 women in the control group. Overall prescription fills in the first and second trimester was 55.3% and 44.7% (intervention group) and 49.2% and 51.6% (control group), respectively, as registered in the Norwegian Prescription Database. In total, 16–20% of women in the first trimester and 21–27% of women in the second trimester had a prescription on antiemetic medication. The pharmacist intervention was not associated with women`s self-reported medication use nor prescribed medications in the second trimester. Conclusion The pharmacist consultation had no impact on pregnant women`s use of medications. Future pharmacist consultations should focus on other outcome factors, such as risk perception, knowledge level, and use of other healthcare services.

show abstract

Impact of a primary care pharmacist consultations on pregnant women’s medication use: the SafeStart intervention study linked to a national prescription database

2023

Self Cite

View full text Add to dashboard Cite

Background Prior studies show that pharmacist consultations are highly appreciated by pregnant women and feasible in community pharmacies. However, it is unknown whether such counseling has an impact on medication use during pregnancy. Aim This study aimed to assess whether a pharmacist consultation in early pregnancy was associated with pregnant women’s medication use, with a focus on antiemetic medications. Method The SafeStart study recruited Norwegian pregnant women in the first trimester between February 2018 and February 2019. Women in the intervention group received a pharmacist consultation in a community pharmacy or by phone. A follow-up questionnaire was completed 13 weeks after enrollment. Data from the SafeStart study were linked to the Norwegian Prescription Database. Logistic regression was used to assess the association between the pharmacist intervention and medication use in the second trimester. Results The study included 103 women in the intervention group and 126 in the control group. Overall prescription fills in the first and second trimesters were 55% and 45% (intervention group) and 49% and 52% (control group), respectively. In total, 16–20% of women in the first trimester and 21–27% of women in the second trimester had a prescription for antiemetics. The pharmacist intervention was not associated with women’s medication use in the second trimester. Conclusion This study did not detect an impact of a pharmacist consultation on pregnant women’s use of medications. In the future, pharmacist consultations should focus on other outcome factors, such as risk perception, knowledge level, and the use of other health care services. Trial registration The SafeStart study is registered with ClinicalTrials.gov (identifier: NCT04182750, registration date: December 2, 2019).

show abstract

Use of Decision Support Tools to Empower Pregnant Women: Systematic Review

Cited by 22 publications

References 48 publications

Impact of a Mobile Application for Tracking Nausea and Vomiting During Pregnancy (NVP) on NVP Symptoms, Quality of Life, and Decisional Conflict Regarding NVP Treatments: MinSafeStart Randomized Controlled Trial

Impact of a Mobile Application for Tracking Nausea and Vomiting During Pregnancy (NVP) on NVP Symptoms, Quality of Life, and Decisional Conflict Regarding NVP Treatments: MinSafeStart Randomized Controlled Trial

Impact of a primary care pharmacist intervention on pregnant women`s medication use: The SafeStart intervention study linked to a national prescription database

Impact of a primary care pharmacist consultations on pregnant women’s medication use: the SafeStart intervention study linked to a national prescription database

Contact Info

Product

Resources

About